Expertise in
2
conditions

Lino L. Teichmann

Bonn, NW, DE 
Expertise in
2
conditions
Bonn, NW, DE 

Overview

Lino Teichmann practices practicing medicine in Bonn, Germany.

Mr. Teichmann is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Essential Thrombocythemia, Myelofibrosis, and Chronic Myelogenous Leukemia (CML).

He is actively involved in clinical research, co-authoring 26 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Bonn, NW 53127, Germany
Other Locations
Aachen, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3

26 Total Publications

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.
DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.
Journal: BMC cancer
Published: June 16, 2026

Frequently Asked Questions about Lino L. Teichmann

Is Lino L. Teichmann a top-rated expert for Myeloproliferative Neoplasms (MPN)?

MediFind is an objective health platform that identifies experts based on real-world data. Lino L. Teichmann is classified as an Advanced expert for Myeloproliferative Neoplasms (MPN), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Lino L. Teichmann participate in research or clinical trials?

Yes. Lino L. Teichmann has published 26 articles and abstracts on conditions like Myeloproliferative Neoplasms (MPN). You can view a list of Lino L. Teichmann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Teichmann's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile